All Fulcrum Publications

April 22, 2023

Muscle Ultrasound in an Open-Label Study of Losmapimod in Subjects with FSHD1

Kools J, N Voermans, K Mul, J Jiang, M Karlsson

March 19, 2023

Results from 96 Weeks of Dosing from the Open-Label Extension of a Phase 2 Trial of Losmapimod in Subjects with FSHD: ReDUX4

Wang L, J Han, J Jiang, R Tawil

October 11, 2022

Measuring Progression in FSHD: Implications for Clinical Trials

Shoskes J, L Wang, S Sacconi

August 1, 2022

Quantitative Muscle Analysis in FSHD Using Whole-Body Fat-Referenced MRI: Composite Scores for Longitudinal and Cross-sectional Analysis

Mellion ML, P Widholm, M Karlsson, A Ahlgren, R Tawil, KR Wagner, JM Statland, L Wang, PB Shieh, BGM van Engelen, J Kools, L Ronco, A Odueyungbo, J Jiang, JJ Han, M Hatch, J Towles, O Dahlqvist Leinhard, D Cadavid

August 1, 2022

Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole-body fat-referenced MRI: Protocol development, multicenter feasibility, and repeatability

Quantitative muscle analysis in facioscapulohumeral muscular dystrophy using whole-body fat-referenced MRI: Protocol development, multicenter feasibility, and repeatability Widholm P, A Ahlgren, M Karlsson, T Romu, R Tawil, KR Wagner, JM Statland, LH Wang, PB Shieh, BGM van Engelen, D Cadavid, L Ronco, AO Odueyungbo, JG Jiang, ML Mellion, O Dahlqvist Leinhard Muscle Nerve 2022 Aug 66(2):183-192 doi: 10.1002/mus.27638 https://pubmed.ncbi.nlm.nih.gov/35585766/

June 10, 2022

Initial Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Data from an Ongoing Open-Label Study Investigating FTX-6058 in Adults Living with Sickle Cell Disease

Julie Kanter, Jae Ahn, Geoff Allen, Paul Bruno, Judy Dunn, Olga Mitelman, Chris Morabito, Billy Stuart, William Tracewell, John Ziegler

June 10, 2022

Inhibition of Polycomb Repressive Complex 2 Through EED Induces Fetal Hemoglobinin Healthy and Sickle Cell Disease Models

Billy Stuart, Paul Bruno, Damon Polioudakis, Mark Roth, Mary Wertz, Alexander Edelstein, Ivan Efremov, David Matson, Judy Dunn

April 4, 2022

A phase 2, randomized, double-blind, placebo-controlled, 48-Week study of the efficacy and safety of losmapimodin subjects with FSHD: ReDUX4

Christopher Morabito, MD, CMO

April 4, 2022

An Open-Label Study of Losmapimod to Evaluate the Safety, Tolerability, and Biomarker and Clinical Outcome Assessment Changes in Subjects with FSHD1

Joost Kools, Nicol Voermans, Karlien Mul, Lucienne Ronco, John Jiang, Jennifer Shoskes, Kelly Marshall, Diego Cadavid, Michelle L. Mellion, Baziel van Engelen

April 4, 2022

Quantitative MuscleAnalysis in FSHD Using Whole-Body MRI: Composite Muscle Measurements for Cross-Sectional Analysis

Per Widholm, Markus Karlsson, André Ahlgren, Olof Dahlqvist-Leinhard, Rabi Tawil, Kathryn Wagner, Jeffrey Statland, Leo Wang, Perry Shieh, Baziel Van Engelen, Diego Cadavid, Lucienne Ronco, Adefowope Odueyungbo, Jay Han, Maya Hatch, Michelle L. Mellion